作者: Kenta Masui , Webster K. Cavenee , Paul S. Mischel
DOI: 10.1111/BPA.12307
关键词:
摘要: Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid growth. Understanding how oncogenes coordinate altered signaling with metabolic cancer harness cellular metabolism its metabolites their survival may yield new insights into pathogenesis. Here, we review recently identified regulatory role mTORC2, downstream effector many cancer-causing mutations, in drug resistance glioblastoma. We further consider emerging concept that mTORC2 connect genetics environmental alterations brain cancer.